Super Generics Market Size Will Reach USD 128.62 Billion to 2031 - Revealed InsightAce Latest Study [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
Super Generics Market –By Therapeutic Area (Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders and Other Disorders), By Route of Administration (Intravenous, Oral, Subcutaneous and Others), By Type of Molecule (Small and Other Molecules), By Type of Small Molecule (Generics and Other Small Molecules), By Type of Product (Aerosols, Capsules, Prefilled Syringes, Tablets, Vials and Other Products)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Super Generics Market is valued at US$ 73.06 Bn in 2023 , and it is expected to reach US$ 128.62 Bn by 2031, with a CAGR of 7.32% during the forecast period of 2024-2031 Download Free Report Sample Pages @ https://www.insightaceanalytic.com/request-sample/2437 The Super Generics market encompasses an advanced category of generic drugs designed to offer additional benefits beyond traditio
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.Business Wire
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Nestlé signs India venture with pharma group Dr Reddy's [Yahoo! Finance]Yahoo! Finance
- Indian shares set to open lower on fading US rate cut hopes [Reuters]Reuters
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
RDY
Earnings
- 1/31/24 - Beat
RDY
Sec Filings
- 5/3/24 - Form 6-K
- 4/30/24 - Form 6-K
- 4/25/24 - Form 6-K
- RDY's page on the SEC website